Loading...
•
Mar 31, 2023
Nkarta Q1 2023 Earnings Report
Reported financial results for the first quarter ended March 31, 2023.
Key Takeaways
Nkarta reported cash and cash equivalents of $332.1 million as of March 31, 2023. The company's net loss for the quarter was $30.8 million, or $0.63 per share. Nkarta expects its current cash and cash equivalents will be sufficient to fund its current operating plan into 2025.
Clinical updates on track for NKX101 in the second quarter of 2023 and NKX019 in the second half of 2023.
Nkarta plans to present additional clinical data in the second quarter of 2023 from its ongoing Phase 1 clinical trial of NKX101 in patients with relapsed or refractory acute myeloid leukemia (r/r AML).
Nkarta plans to present additional clinical data in the second half of 2023 from its ongoing Phase 1 clinical trial of NKX019 in patients with relapsed or refractory non-Hodgkin lymphoma (r/r NHL).
Cash and cash equivalents totaled $332.1 million on March 31, 2023, expected to fund operations into 2025.
Forward Guidance
Nkarta expects its current cash and cash equivalents will be sufficient to fund its current operating plan into 2025.
Historical Earnings Impact
Analyze how earnings announcements historically affect stock price performance
Avg. Return Before/After Earnings
Loading earnings performance data...
Loading earnings reaction data...